Xiang Shu, PhD, MS

Assistant Attending

Xiang Shu, PhD, MS

Assistant Attending
Xiang Shu

Office Phone



The University of Texas Health Science Center

Current Research Interests

Dr. Shu’s research primarily focuses on identifying novel genetic and molecular markers for cancer risk, with the goal of better understanding tumorigenesis and providing novel tools for risk assessment. Dr. Shu is actively participating in multiple international consortia including the Breast Cancer Association Consortium, the Asia Breast Cancer Consortium, the Genetics and Epidemiology of Colorectal Cancer Consortium. Dr. Shu is an NCI R00 award recipient and his recent work using integrated omics approaches provides new insights into the etiology of colorectal cancer. He is also an active investigator in three large prospective cohorts, the Shanghai Women’s Health Study (SWHS), the Shanghai Men’s Health Study (SMHS), and the Southern Community Cohort Study (SCCS), leading several prospective metabolomics and proteomics projects to uncover novel risk biomarkers for colorectal, pancreatic, and gastric cancer. After joining the department in 2020, Dr. Shu has also extended his interest to patient-oriented research such as identifying genetic risk factors for contralateral breast cancer and intrinsic subtypes of breast cancer.


  1. Shu X, Chen Z, Long J, Guo X, Yang Y, Qu C, Ahn YO, Cai Q, Casey G, Gruber SB, Huyghe JR, Jee, SH, Jenkins MA, Jia WH, Jung KJ, Kamatani Y, Kim DH, Kim J, Kweon SS, Le Marchand L, Matsuda K, Matsuo K, Newcomb PA, Oh JH, Ose J, Oze I, Pai RK, Pan ZZ, Pharoah PDP, Playdon MC, Ren ZF, Schoen RE, Shin A, Shin MH, Shu XO, Sun X, Tangen CM, Tanikawa C, Ulrich CM, Van Duijnhoven FJB, Van Guelpen B, Wolk A, Woods MO, Wu AH, Peters U, Zheng W. Large-scale integrated analysis of genetics and metabolomic data reveals potential lipid biomarkers for colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2022 Jun 1;31(6):1216-1226. Featured article in the “Cancer Epidemiology, Biomarkers & Prevention Highlights: Selected Articles from This Issue.
  2. Jia G, Ping J, Shu X, Yang Y, Cai Q, Kweon SS, Choi JY, Kubo M, Park SK, Bolla MK, Dennis J, Wang Q, Guo X, Li B, Tao R, Aronson KJ, Chan TL, Gao YT, Hartman M, Ho WK, Ito H, Iwasaki M, Iwata H, John EM, Kasuga Y, Kim MK, Kurian AW, Kwong A, Li J, Lophatananon A, Low SK, Mariapun S, Matsuda K, Matsuo K, Muir K, Noh DY, Park B, Park MH, Shen CY, Shin MH, Spinelli JJ, Takahashi A, Tseng C, Tsugane S, Wu AH, Yamaji T, Zheng Y, Dunning AM, Pharoah PDP, Teo SH, Kang D, Easton DF, Simard J, Shu XO, Long J, Zheng W. Genome- and transcriptome-wide association studies of 386,000 Asian and European-ancestry women provide new insights into breast cancer genetics. Am J Hum Genet. 2022 Nov 3:S0002-9297(22)00459-1.
  3. Shu X, Zhou Q, Sun X, Flesaker M, Guo X, Long J, Robson ME, Shu XO, Zheng W, Bernstein JL. Associations between circulating proteins and risk of breast cancer by intrinsic subtypes: a Mendelian randomisation analysis. Br J Cancer. 2022 Nov;127(8):1507-1514.
  4. Sun X, Shu XO, Lan Q, Laszkowska M, Cai Q, Rothman N, Wen W, Zheng W, Shu X. Prospective Proteomic Study Identifies Potential Circulating Protein Biomarkers for Colorectal Cancer Risk. Cancers (Basel). 2022 Jul 3;14(13):3261.
  5. Yang Y, Long J, Wang C, Blot WJ, Pei Z, Shu X, Wu F, Rothman N, Wu J, Lan Q, Cai Q, Zheng W, Chen Y, Shu XO. Prospective study of oral microbiome and gastric cancer risk among Asian, African American and European American populations. Int J Cancer. 2022 Mar 15;150(6):916-927.

View a full listing of Xiang Shu’s journal articles.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Xiang Shu discloses the following relationships and financial interests:

No disclosures meeting criteria for time period

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures